- Home
- MTEX vs EQ Comparison
MTEX vs EQ Comparison
Compare MTEX & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- EQ
- Stock Information
- Founded
- MTEX 1993
- EQ 2017
- Country
- MTEX United States
- EQ United States
- Employees
- MTEX N/A
- EQ N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- MTEX Health Care
- EQ Health Care
- Exchange
- MTEX Nasdaq
- EQ Nasdaq
- Market Cap
- MTEX 28.2M
- EQ 24.8M
- IPO Year
- MTEX 1999
- EQ 2018
- Fundamental
- Price
- MTEX $11.00
- EQ $0.64
- Analyst Decision
- MTEX
- EQ Buy
- Analyst Count
- MTEX 0
- EQ 2
- Target Price
- MTEX N/A
- EQ $5.00
- AVG Volume (30 Days)
- MTEX 6.2K
- EQ 141.5K
- Earning Date
- MTEX 11-12-2024
- EQ 11-13-2024
- Dividend Yield
- MTEX N/A
- EQ N/A
- EPS Growth
- MTEX N/A
- EQ N/A
- EPS
- MTEX N/A
- EQ N/A
- Revenue
- MTEX $121,552,000.00
- EQ $45,914,000.00
- Revenue This Year
- MTEX N/A
- EQ $4.76
- Revenue Next Year
- MTEX N/A
- EQ N/A
- P/E Ratio
- MTEX N/A
- EQ N/A
- Revenue Growth
- MTEX N/A
- EQ 7.70
- 52 Week Low
- MTEX $6.75
- EQ $0.56
- 52 Week High
- MTEX $15.83
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- MTEX 42.49
- EQ 39.10
- Support Level
- MTEX $13.84
- EQ $0.64
- Resistance Level
- MTEX $15.83
- EQ $0.73
- Average True Range (ATR)
- MTEX 1.20
- EQ 0.08
- MACD
- MTEX -0.48
- EQ -0.00
- Stochastic Oscillator
- MTEX 11.38
- EQ 10.12
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.